Research Library
Curated Studies & Clinical Data
A growing library of peer-reviewed studies, clinical trial data, and systematic reviews organized by compound. Every citation is linked to its primary source.
OAF Blocks SIAH1-Mediated Degradation of SCPX, a Therapeutic Strategy for MASLD
Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026;:e77451
Effects of subcutaneous semaglutide on weight loss and inflammatory markers in adults with overweight or obesity without diabetes: a systematic review and meta-analysis
International journal of obesity (2005), 2026
Drug failure in diabetic kidney disease: translational barriers, target validation and trial de-risking strategies
Biochemical pharmacology, 2026;:118405
Effects of semaglutide and empagliflozin on markers of endothelial function in persons with type 2 diabetes: A post hoc analysis of a randomized clinical trial
Journal of diabetes and its complications, 2026;40(10):109397
Comparative effectiveness of GLP-1 receptor agonists versus mineralocorticoid receptor antagonists as fourth-line pharmacological therapy in patients with resistant hypertension and overweight or obesity: a retrospective multicenter cohort study in the USA
EClinicalMedicine, 2026;99:104176
Semaglutide in Japanese participants with metabolic dysfunction-associated steatohepatitis: a subgroup analysis of the ESSENCE trial
Journal of gastroenterology, 2026
Dramatic Improvement of Treatment-Refractory Prurigo Nodularis Following Initiation of Semaglutide: A Case Report
Clinical, cosmetic and investigational dermatology, 2026;19:606727
Oral small-molecule GLP-1 receptor agonists: a new Frontier in cardiometabolic medicine
Frontiers in pharmacology, 2026;17:1933018
Case Report: Tirzepatide improves glycemic control in Rabson-Mendenhall syndrome
Frontiers in endocrinology, 2026;17:1945251
Data and Temporal Risk Concerns of Semaglutide and NAION-Reply
JAMA ophthalmology, 2026
Data and Temporal Risk Concerns of Semaglutide and NAION
JAMA ophthalmology, 2026
Effects of Semaglutide versus Bariatric Surgery on Noninvasive Markers of Hepatic Steatosis and Fibrosis in Obesity with MASLD
The Journal of clinical endocrinology and metabolism, 2026
Transcriptomic Changes Elicited by Semaglutide in Human Ventricular Tissue Support Cell Survival and Lipid Metabolism
Circulation. Heart failure, 2026;:e014421
Tirzepatide as a possible trigger of bullous pemphigoid: A case report
Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2026
From adiposity to multisystem morbidity: the case for weight loss as disease modification
The lancet. Diabetes & endocrinology, 2026
Comparative efficacy and safety of glucagon-like peptide 1 based drugs for weight loss in adults with overweight or obesity without diabetes: network meta-analysis of randomised controlled trials
BMJ medicine, 2026;5(1):e003026
Reporting patterns of suicide- and self-injury-related events involving liraglutide, semaglutide, and tirzepatide: data from the European pharmacovigilance database
Frontiers in pharmacology, 2026;17:1882225
Estimating treatment effects in clinical studies of Alzheimer’s disease: What are estimands and why do we need them?
Alzheimer's & dementia : the journal of the Alzheimer's Association;22(8):e71676
Body Composition and Lifestyle Interventions in Pharmacological Treatment of Acquired Hypothalamic Obesity: A Systematic Review of Randomized Controlled Trials
Obesity (Silver Spring, Md.);34(9):1687-1698
IDE-mediated GLP-1 degradation as the basis for designing long-acting and CNS-stable GLP-1 receptor agonists
Science advances, 2026;12(35):eaeh4670